NOVARTIS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 92.32 CHF | +1.97% |
|
+4.94% | +8.78% |
| 05-10 | Novartis’ Scemblix Gets Third US FDA Breakthrough Therapy Designation | MT |
| 05-10 | Novartis Gets FDA Breakthrough Therapy Designation for Scemblix | DJ |
ETFs positioned on Novartis AG
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.51% | 786 M€ | -.--% | ||
| 0.51% | 23 M€ | -.--% | - | |
| 0.50% | 206 M€ | -.--% | ||
| 0.48% | 205 M€ | -.--% | ||
| 0.47% | 0 M€ | +8.33% | ||
| 0.39% | 0 M€ | +18.92% | ||
| 0.37% | 1,166 M€ | +0.26% | ||
| 0.37% | 607 M€ | +0.05% | ||
| 0.30% | 0 M€ | +2.59% | - | |
| 0.26% | 0 M€ | +8.70% | - | |
| 0.23% | 0 M€ | +8.24% | - | |
| 0.22% | 0 M€ | 0.00% | - | |
| 0.17% | 0 M€ | +5.79% | - | |
| 0.17% | 0 M€ | +5.63% | - | |
| 0.13% | 0 M€ | +3.50% | - | |
| 0.12% | 0 M€ | +2.80% | - | |
| 0.09% | 0 M€ | +3.63% | - | |
| 0.08% | 0 M€ | +2.72% | - | |
| 0.06% | 0 M€ | +0.32% | - | |
| 0.06% | 0 M€ | +0.50% | - |
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows:
- oncology (29.9%);
- immunology (17.2%);
- cardiovascular, renal and metabolic diseases (14.1%);
- neuroscience (8.9%).
The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products.
At the end of 2023, Novartis AG had 33 production sites worldwide.
Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
101.8
USD
Average target price
108.4
USD
Spread / Average Target
+6.52%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +8.78% | 208B | |
| +30.38% | 684B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.70% | 240B | |
| -7.93% | 200B | |
| +7.68% | 166B | |
| -2.71% | 159B |
- Stock Market
- Equities
- NOVN Stock
- Funds and ETFs Novartis AG